Information Provided By: 
Fly News Breaks for October 1, 2018
ONCY
Oct 1, 2018 | 07:35 EDT
Ladenburg Thalmann analyst Wangzhi Li started Oncolytics Biotech with a Buy rating and $22 price target. The analyst believes Oncolytics is "significantly under-recognized and undervalued, and presents an attractive investment opportunity." The company's lead program Pelareorep is a RNA reovirus oncolytic virus that has been safely dosed in greater than 1,100 patients across a variety of cancers, Li points out.
News For ONCY From the Last 2 Days
There are no results for your query ONCY
